Thursday, July 10, 2014





Generic competition, charges cut Merck Q4 profit


February 20. 2013 4:32AM
Story Tools
PrintPrint | E-MailEMail | SaveSave | Hear Generate QR Code QR
Send to Kindle


(AP) Merck & Co. says its fourth-quarter profit fell 7 percent as generic competition slashed sales of its blockbuster allergy drug Singulair and the drugmaker took sizeable restructuring and acquisition charges.


The world's third-biggest drugmaker by revenue says net income was $1.4 billion, or 46 cents per share, down from $1.51 billion, or 49 cents per share, a year earlier.


Excluding one-time charges totaling $1.14 billion, net income was $2.54 billion, or 83 cents per share, 2 cents more than analysts polled by FactSet were expecting.


The maker of Januvia and other diabetes pills says revenue totaled $11.74 billion, down 5 percent from 2011's fourth quarter. Analysts expected revenue of $11.47 billion.


Merck, which is based in Whitehouse Station, N.J., forecast 2013 earnings per share of $3.60 to $3.70, excluding charges.


Associated Press


Comments
comments powered by Disqus Commenting Guidelines
Poll
Mortgage Minute


Search for New & Used Cars

Make 
Model
 
Used New All
 

Search Times Leader Classifieds to find just the home you want!

Search Times Leader Classifieds to find just what you need!

Search Pet Classifieds
Dogs Cats Other Animals



Social Media/RSS
Times Leader on Twitter
Times Leader on Youtube
Times Leader on Google+
The Times Leader on Tumblr
The Times Leader on Pinterest
Times Leader RSS Feeds